Post-trial follow-up | Pembrolizumab vs. chemotherapy as first-line therapy in PD-L1-expressing non–small-cell lung cancer. 31 Oct, 2022 | 13:39h | UTC Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study – Journal of Clinical Oncology Original Study: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial – The Lancet